Neuroblastoma xenograft models demonstrate the therapeutic potential of ¹⁷⁷Lu-octreotate.

ABSTRACT:

Background

Neuroblastoma (NB) is one of the most frequently diagnosed tumors in infants. NB is a neuroendocrine tumor type with various characteristics and features, and with diverse outcome. The most malignant NBs have a 5-year survival rate of only 40-50%, indicating the need for novel and improved treatment options. ¹⁷⁷Lu-octreotate is routinely administered for treatment of neuroendocrine tumors overexpressing somatostatin receptors (SSTR). The aim of this study was to examine the biodistribution of ¹⁷⁷Lu-octreotate in mice bearing aggressive human NB cell lines, in order to evaluate the potential usefulness of ¹⁷⁷Lu-octreotate for treatment of NB.

Methods

BALB/c nude mice bearing CLB-BAR, CLB-GE or IMR-32 tumor xenografts (n = 5-7/group)

SUBMITTER: Romiani A 

PROVIDER: S-EPMC8386073 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature